| Year |
Citation |
Score |
| 2024 |
Greengard E, Williams R, Moriarity B, Liu X, Minard CG, Reid JM, Fisher T, Evans E, Pastore DR, Zauderer M, Voss S, Fox E, Weigel BJ. A phase 1/2 study of pepinemab in children, adolescents, or young adults with recurrent or refractory solid tumors: A children's oncology group consortium report (ADVL1614). Pediatric Blood & Cancer. e30938. PMID 38520670 DOI: 10.1002/pbc.30938 |
0.368 |
|
| 2023 |
Smith ES, Balch LA, Scrivens M, Shi S, Wang W, Harvey CD, Cornelison AA, Gil-Moore M, Kirk RA, Mueller LL, Hall RL, Howell AP, Reilly CA, Mayer JM, Murante FG, ... ... Zauderer M, et al. Use of poxvirus display to select antibodies specific for complex membrane antigens. Mabs. 15: 2249947. PMID 37635331 DOI: 10.1080/19420862.2023.2249947 |
0.556 |
|
| 2023 |
Klenk C, Scrivens M, Niederer A, Shi S, Mueller L, Gersz E, Zauderer M, Smith ES, Strohner R, Plückthun A. A Vaccinia-based system for directed evolution of GPCRs in mammalian cells. Nature Communications. 14: 1770. PMID 36997531 DOI: 10.1038/s41467-023-37191-8 |
0.493 |
|
| 2021 |
Shafique M, Fisher TL, Evans EE, Leonard JE, Pastore DRE, Mallow CL, Smith ES, Mishra V, Schröder A, Chin K, Beck JT, Baumgart MA, Govindan R, Gabrail NY, Spira AI, ... ... Zauderer M, et al. A Phase 1b/2 Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33820783 DOI: 10.1158/1078-0432.CCR-20-4792 |
0.324 |
|
| 2021 |
Kharkwal SS, Johndrow CT, Veerapen N, Kharkwal H, Saavedra-Avila NA, Carreño LJ, Rothberg S, Zhang J, Garforth SJ, Jervis PJ, Zhang L, Donda A, Besra AK, Cox LR, Almo SC, ... ... Zauderer M, et al. Serial Stimulation of Invariant Natural Killer T Cells with Covalently Stabilized Bispecific T Cell Engagers Generates Anti-Tumor Immunity While Avoiding Anergy. Cancer Research. PMID 33483371 DOI: 10.1158/0008-5472.CAN-20-2219 |
0.408 |
|
| 2020 |
Shafique MR, Fisher TL, Evans EE, Leonard JE, Pastore DRE, Mallow CL, Smith E, Schröder A, Chin KM, Beck JT, Baumgart MA, Govindan R, Gabrail NY, Sanborn RE, Spira AI, ... ... Zauderer M, et al. Interim results from a phase Ib/II study of pepinemab in combination with avelumab in advanced NSCLC patients following progression on prior systemic and/or anti-PDx therapies. Journal of Clinical Oncology. 38: 75-75. DOI: 10.1200/Jco.2020.38.5_Suppl.75 |
0.347 |
|
| 2020 |
Ruffolo LI, Ullman NA, Dale B, Jackson KM, Burchard P, Georger M, Jewell R, Belt BA, Galka E, Schoeniger LO, Mallow CL, Evans EE, Fisher TL, Zauderer M, Linehan D. Antibody blockade of semaphorin 4D to sensitize pancreatic cancer to immune checkpoint blockade. Journal of Clinical Oncology. 38: 26-26. DOI: 10.1200/Jco.2020.38.5_Suppl.26 |
0.373 |
|
| 2020 |
Shafique MR, Fisher TL, Evans EE, Leonard JE, Pastore DRE, Mallow CL, Smith E, Schröder A, Chin KM, Beck JT, Baumgart MA, Govindan R, Gabrail NY, Sanborn RE, Spira AI, ... ... Zauderer M, et al. Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase Ib/II study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC. Journal of Clinical Oncology. 38: 3011-3011. DOI: 10.1200/Jco.2020.38.15_Suppl.3011 |
0.404 |
|
| 2020 |
Evans EE, Lesinski GB, Fisher TL, Mallow C, Olson B, Clavijo PE, Leonard JE, Pastore DR, Smith ES, Zauderer M, Allen CT, Lowe M, Kudchadkar R, Wu C, Steuer C, et al. Abstract A15: Integrated biomarker trials to evaluate myeloid and lymphoid composition of HNSCC and solid tumors treated with pepinemab and combinations with checkpoint inhibitors Clinical Cancer Research. 26. DOI: 10.1158/1557-3265.Aacrahns19-A15 |
0.517 |
|
| 2019 |
Das R, Guan P, Wiener SJ, Patel NP, Gohl TG, Evans E, Zauderer M, Nichols KE. Enhancing the antitumor functions of invariant natural killer T cells using a soluble CD1d-CD19 fusion protein. Blood Advances. 3: 813-824. PMID 30858151 DOI: 10.1182/Bloodadvances.2018028886 |
0.431 |
|
| 2019 |
Shafique MR, Fisher TL, Evans EE, Leonard JE, Pastore DRE, Mallow CL, Smith E, Zauderer M, Schröder A, Chin KM, Beck JT, Baumgart MA, Govindan R, Sanborn RE, Goldman JW. Preliminary results from CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC. Journal of Clinical Oncology. 37: 2601-2601. DOI: 10.1200/Jco.2019.37.15_Suppl.2601 |
0.364 |
|
| 2019 |
Evans EE, Bussler H, Mallow C, Reilly C, Torno S, Scrivens M, Howell A, Balch L, Leonard JE, Fisher TL, Allen C, Clavijo P, Lesiniski G, Wu C, Hu-Lieskovan S, ... ... Zauderer M, et al. Abstract PR10: Reprogramming myeloid cells in TME with pepinemab, first-in-class semaphorin 4D MAb, enhances combination immunotherapy Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-Pr10 |
0.539 |
|
| 2019 |
Lesinski GB, Fisher TL, Evans EE, Leonard JE, Pastore DR, Mallow C, Smith E, Zauderer M, Steuer C, Saba NF, Lowe M, Kudchadkar RR, Olson B, Wu C. Abstract CT016: Integrated biomarker trials of VX15/2503 (pepinemab) in combination with checkpoint inhibitors in window of opportunity studies in solid tumors Clinical Trials. DOI: 10.1158/1538-7445.Sabcs18-Ct016 |
0.33 |
|
| 2019 |
Ruffolo LI, Jackson KM, Ullman N, Chacon A, Melucci A, Burchard P, Georger M, Jewell R, Prieto P, Belt B, Mallow C, Evans E, Fisher T, Zauderer M, Wu C, et al. Abstract B48: Targeting the semaphorin 4D-plexin B axis to augment FOLFIRINOX in a murine model of pancreatic adenocarcinoma Cancer Research. 79. DOI: 10.1158/1538-7445.Panca19-B48 |
0.477 |
|
| 2019 |
Shafique M, Fisher TL, Evans EE, Leonard JE, Pastore DR, Mallow C, Smith E, Zauderer M, Schröeder A, Chin K, Beck T, Baumgart M, Sanborn RE, Goldman JW. Abstract CT086: Interim results from CLASSICAL-Lung, a Phase Ib/II study of VX15/2503 (pepinemab) in combination with avelumab in advanced NSCLC Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct086 |
0.4 |
|
| 2019 |
Evans EE, Fisher TL, Bussler H, Mallow C, Reilly C, Torno S, Pastore DR, Scrivens M, Howell A, Balch L, Leonard JE, Allen C, Clavijo PE, Lesinski G, Wu C, ... ... Zauderer M, et al. Abstract 1545: Altered myeloid and lymphoid composition of tumor microenvironment following anti-SEMA4D and immune checkpoint combination therapies Cancer Research. 79: 1545-1545. DOI: 10.1158/1538-7445.Am2019-1545 |
0.533 |
|
| 2019 |
Fisher TL, Evans EE, Leonard JE, Reader AM, Mallow CL, Balch L, Howell A, Smith ES, Zauderer M, Feigin A. P3-007: Vx15 Anti-Semaphorin 4D Antibody (Pepinemab) Increases Fdg-Pet Signal And Is A Potential Treatment For Alzheimer'S Disease Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.3033 |
0.309 |
|
| 2018 |
Clavijo PE, Friedman J, Robbins Y, Moore EC, Smith ES, Zauderer M, Evans EE, Allen CT. Semaphorin4D inhibition improves response to immune checkpoint blockade via attenuation of MDSC recruitment and function. Cancer Immunology Research. PMID 30514791 DOI: 10.1158/2326-6066.Cir-18-0156 |
0.479 |
|
| 2018 |
Kharkwal SS, Veerapen N, Jervis P, Bhowruth V, Besra AK, North SJ, Haslam SM, Dell A, Hobrath J, Quaid P, Moynihan P, Cox LR, Kharkwal H, Zauderer M, Besra GS, et al. Photoactivable glycolipid antigens generate stable conjugates with CD1d for invariant Natural Killer T cell activation. Bioconjugate Chemistry. PMID 30085659 DOI: 10.1021/Acs.Bioconjchem.8B00484 |
0.375 |
|
| 2018 |
Evans EE, Bussler H, Mallow C, Reilly C, Torno S, Scrivens M, Foster C, Howell A, Balch L, Leonard JE, Fisher TL, Allen C, Clavijo P, Hu-Leiskovan S, Ribas A, ... ... Zauderer M, et al. Abstract PR09: Breaking down barriers restricting myeloid cell differentiation and infiltration in the tumor microenvironment with a first-in-class antibody targeting semaphorin4D, and rational combination therapies Cancer Immunology Research. 6. DOI: 10.1158/2326-6074.Tumimm17-Pr09 |
0.538 |
|
| 2018 |
Evans EE, Bussler H, Mallow C, Reilly C, Torno S, Scrivens M, Howell A, Balch L, Leonard JE, Fisher T, Allen C, Clavijo PE, Lesinski G, Wu C, Hu-Lieskovan S, ... ... Zauderer M, et al. Abstract 1762: Shifting the tumor microenvironment with first-in-class semaphorin 4D mab for combination immunotherapy Cancer Research. 78: 1762-1762. DOI: 10.1158/1538-7445.Am2018-1762 |
0.517 |
|
| 2018 |
Evans EE, Bussler H, Mallow C, Reilly C, Torno S, Scrivens M, Foster C, Howell A, Balch L, Leonard JE, Fisher TL, Allen C, Clavijo P, Hu-Lieskovan S, Ribas A, ... ... Zauderer M, et al. Abstract B199: Targeting the tumor microenvironment with first-in-class Semaphorin4D MAb for combination immunotherapy Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-B199 |
0.541 |
|
| 2017 |
LaGanke C, Samkoff L, Edwards K, Jung Henson L, Repovic P, Lynch S, Stone L, Mattson D, Galluzzi A, Fisher TL, Reilly C, Winter LA, Leonard JE, Zauderer M. Safety/tolerability of the anti-semaphorin 4D Antibody VX15/2503 in a randomized phase 1 trial. Neurology(R) Neuroimmunology & Neuroinflammation. 4: e367. PMID 28642891 DOI: 10.1212/Nxi.0000000000000367 |
0.309 |
|
| 2017 |
Evans EE, Bussler H, Mallow C, Reilly C, Torno S, Scrivens M, Foster C, Howell A, Comeau SR, Balch L, Knapp A, Leonard JE, Fisher TL, Hu-Lieskovan S, Ribas A, ... ... Zauderer M, et al. Abstract 3661: Breaking down the barrier restricting infiltration and differentiation of APC in the tumor microenvironment with a first-in-class antibody targeting Semaphorin4D, and rational combination therapies Cancer Research. 77: 3661-3661. DOI: 10.1158/1538-7445.Am2017-3661 |
0.538 |
|
| 2016 |
Evans EE, Bussler H, Torno S, Mallow C, Winters LA, Reilly C, Klimatcheva E, Veeraraghavan J, Jonason AS, Scrivens M, Kirk R, Howell A, Balch L, Leonard JE, Paris M, ... ... Zauderer M, et al. Abstract A119: Antibody blockade of Semaphorin 4D neutralizes barrier to immune infiltration and facilitates immune-mediated tumor rejection Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-A119 |
0.549 |
|
| 2016 |
Evans EE, Bussler H, Mallow C, Reilly C, Torno S, Klimatcheva E, Scrivens M, Foster C, Howell A, Balch L, Knapp A, Leonard JE, Paris MJ, Fisher TL, Hu-Lieskovan S, ... ... Zauderer M, et al. Abstract B023: Antibody blockade of Semaphorin 4D enhances infiltration of APC and CD8 T cells and reduces immune suppression to facilitate immune-mediated tumor rejection Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-B023 |
0.55 |
|
| 2016 |
Evans EE, Bussler H, Torno S, Mallow C, Reilly C, Scrivens M, Klimatcheva E, Winter LA, Kirk R, Howell A, Balch L, Leonard JE, Paris M, Fisher TL, Hu-Lieskovan S, ... ... Zauderer M, et al. Abstract 4888: Antibody blockade of semaphorin 4D breaks down stromal barriers to enhance tumoricidal immune infiltration, supporting rational immunotherapy combinations Cancer Research. 76: 4888-4888. DOI: 10.1158/1538-7445.Am2016-4888 |
0.539 |
|
| 2015 |
Evans EE, Paris M, Smith ES, Zauderer M. Immunomodulation of the tumor microenvironment by neutralization of Semaphorin 4D. Oncoimmunology. 4: e1054599. PMID 26587332 DOI: 10.1080/2162402X.2015.1054599 |
0.501 |
|
| 2015 |
Fisher TL, Seils J, Reilly C, Litwin V, Green L, Salkowitz-Bokal J, Walsh R, Harville S, Leonard JE, Smith E, Zauderer M. Saturation monitoring of VX15/2503, a novel semaphorin 4D-specific antibody, in clinical trials. Cytometry. Part B, Clinical Cytometry. PMID 26566052 DOI: 10.1002/Cyto.B.21338 |
0.401 |
|
| 2015 |
Patnaik A, Weiss GJ, Leonard JE, Rasco D, Sachdev JC, Fisher TL, Winter LA, Reilly C, Parker RB, Mutz D, Blaydorn L, Tolcher AW, Zauderer M, Ramanathan RK. Safety, Pharmacokinetics and Pharmacodynamics of a Humanized anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26446947 DOI: 10.1158/1078-0432.Ccr-15-0431 |
0.407 |
|
| 2015 |
Fisher TL, Reilly CA, Winter LA, Pandina T, Jonason A, Scrivens M, Balch L, Bussler H, Torno S, Seils J, Mueller L, Huang H, Klimatcheva E, Howell A, Kirk R, ... ... Zauderer M, et al. Generation and preclinical characterization of an antibody specific for SEMA4D. Mabs. 0. PMID 26431358 DOI: 10.1080/19420862.2015.1102813 |
0.43 |
|
| 2015 |
Klimatcheva E, Pandina T, Reilly C, Torno S, Bussler H, Scrivens M, Jonason A, Mallow C, Doherty M, Paris M, Smith ES, Zauderer M. CXCL13 antibody for the treatment of autoimmune disorders. Bmc Immunology. 16: 6. PMID 25879435 DOI: 10.1186/S12865-015-0068-1 |
0.465 |
|
| 2015 |
Southwell AL, Franciosi S, Villanueva EB, Xie Y, Winter LA, Veeraraghavan J, Jonason A, Felczak B, Zhang W, Kovalik V, Waltl S, Hall G, Pouladi MA, Smith ES, Bowers WJ, ... Zauderer M, et al. Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease. Neurobiology of Disease. 76: 46-56. PMID 25662335 DOI: 10.1016/J.Nbd.2015.01.002 |
0.328 |
|
| 2015 |
Leonard JE, Fisher TL, Winter LA, Cornelius CA, Reilly C, Smith ES, Zauderer M. Nonclinical Safety Evaluation of VX15/2503, a Humanized IgG4 Anti-SEMA4D Antibody. Molecular Cancer Therapeutics. 14: 964-72. PMID 25657333 DOI: 10.1158/1535-7163.Mct-14-0924 |
0.367 |
|
| 2015 |
Evans EE, Jonason AS, Bussler H, Torno S, Veeraraghavan J, Reilly C, Doherty MA, Seils J, Winter LA, Mallow C, Kirk R, Howell A, Giralico S, Scrivens M, Klimatcheva K, ... ... Zauderer M, et al. Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies. Cancer Immunology Research. 3: 689-701. PMID 25614511 DOI: 10.1158/2326-6066.Cir-14-0171 |
0.53 |
|
| 2015 |
Evans E, Hu-Lieskovan S, Bussler H, Torno S, Mallow C, Reilly C, Scrivens M, Klimatcheva E, Winter LA, Kirk R, Howell A, Balch L, Veeraraghavan J, Jonason AS, Leonard JE, ... ... Zauderer M, et al. Antibody blockade of Semaphorin 4D breaks down barriers to enhance tumoricidal immune infiltration and supports rational immunotherapy combinations F1000research. 4. DOI: 10.7490/F1000Research.1111176.1 |
0.413 |
|
| 2015 |
Evans EE, Hu-Lieskovan S, Bussler H, Torno S, Mallow C, Reilly C, Scrivens M, Klimatcheva E, Winter LA, Kirk R, Howell A, Balch L, Veeraraghavan J, Jonason AS, Leonard JE, ... ... Zauderer M, et al. Antibody blockade of semaphorin 4D breaks down barriers to enhance tumoricidal immune infiltration and supports rational immunotherapy combinations Journal For Immunotherapy of Cancer. 3: 220. DOI: 10.1186/2051-1426-3-S2-P220 |
0.496 |
|
| 2015 |
Evans EE, Fisher TL, Edington C, Bussler H, Torno S, Jonason AS, Veeraraghavan J, Reilly C, Doherty MA, Seils J, Winter LA, Pandina T, Mallow C, Kirk R, Howell A, ... ... Zauderer M, et al. Abstract A67: Phase 1 study of VX15/2503, an immunomodulatory antibody to Semaphorin 4D that reverses tumor growth in preclinical studies Cancer Immunology Research. 3. DOI: 10.1158/2326-6074.Tumimm14-A67 |
0.515 |
|
| 2015 |
Evans EE, Bussler H, Torno S, Mallow C, Winters LA, Reilly C, Klimatcheva K, Veeraraghavan J, Jonason AS, Scrivens M, Kirk R, Giralico S, Howell A, Leonard JE, Paris M, ... ... Zauderer M, et al. Abstract 278: Antibody blockade of semaphorin 4D promotes infiltration of activated tumor infiltrating leukocytes and reverses tumor growth Immunology. 75: 278-278. DOI: 10.1158/1538-7445.Am2015-278 |
0.445 |
|
| 2014 |
Smith ES, Jonason A, Reilly C, Veeraraghavan J, Fisher T, Doherty M, Klimatcheva E, Mallow C, Cornelius C, Leonard JE, Marchi N, Janigro D, Argaw AT, Pham T, Seils J, ... ... Zauderer M, et al. SEMA4D compromises blood-brain barrier, activates microglia, and inhibits remyelination in neurodegenerative disease. Neurobiology of Disease. 73: 254-268. PMID 25461192 DOI: 10.1016/J.Nbd.2014.10.008 |
0.35 |
|
| 2014 |
Yamamoto K, Nishiumi S, Yang L, Klimatcheva E, Pandina T, Takahashi S, Matsui H, Nakamura M, Zauderer M, Yoshida M, Azuma T. Anti-CXCL13 antibody can inhibit the formation of gastric lymphoid follicles induced by Helicobacter infection. Mucosal Immunology. 7: 1244-54. PMID 24646940 DOI: 10.1038/Mi.2014.14 |
0.306 |
|
| 2014 |
Smith ES, Zauderer M. Antibody library display on a mammalian virus vector: combining the advantages of both phage and yeast display into one technology. Current Drug Discovery Technologies. 11: 48-55. PMID 24090134 DOI: 10.2174/157016381101140124163634 |
0.411 |
|
| 2014 |
Evans EE, Bussler H, Torno S, Veeraraghavan J, Jonason AS, Doherty MA, Reilly C, Mallow C, Seils J, Paris M, Fisher TL, Bowers WJ, Scrivens M, Balch L, Kirk R, ... ... Zauderer M, et al. Abstract 5030: Antibody blockade of Semaphorin 4D promotes tumor rejection and improves response to immune checkpoint blockade and chemotherapy Cancer Research. 74: 5030-5030. DOI: 10.1158/1538-7445.Am2014-5030 |
0.538 |
|
| 2013 |
Corgnac S, Perret R, Derré L, Zhang L, Stirnemann K, Zauderer M, Speiser DE, Mach JP, Romero P, Donda A. CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses. Cancer Immunology, Immunotherapy : Cii. 62: 747-60. PMID 23242316 DOI: 10.1007/S00262-012-1381-7 |
0.476 |
|
| 2013 |
Evans EE, Jonason AS, Paris M, Fisher TL, Torno S, Bussler H, Decker J, Scrivens M, Huang H, Winter LA, Pandina T, Balch L, Doherty MA, Kirk R, Howell A, ... ... Zauderer M, et al. Abstract 1245: Reduction of tumor growth and metastasis by a humanized IgG4 monoclonal antibody to SEMA4D (VX15/2503). Cancer Research. 73: 1245-1245. DOI: 10.1158/1538-7445.Am2013-1245 |
0.524 |
|
| 2012 |
Cornelius CA, Fisher T, Seils J, Winter LA, Jonason AS, Smith E, Watkins R, Zauderer M, Leonard JE. Abstract 936: Nonclinical safety and pharmacology of VX15/2503: a humanized IgG4 monoclonal antibody to SEMA4D Cancer Research. 72: 936-936. DOI: 10.1158/1538-7445.Am2012-936 |
0.45 |
|
| 2011 |
Cornelius CA, Fisher T, Winter LA, Seils J, Reilly CA, Jonason AS, Smith ES, Watkins R, Zauderer M, Leonard JE. Nonclinical safety assessment of a humanized IgG4 anti-SEMA4D antibody to support clinical development. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e13071. PMID 28019916 DOI: 10.1200/Jco.2011.29.15_Suppl.E13071 |
0.42 |
|
| 2011 |
Cornelius CA, Fisher TL, Winter LA, Seils J, Reilly CA, Jonason AS, Smith E, Watkins R, Zauderer M, Leonard JE. Abstract 4578: Nonclinical safety assessment of VX15/2503: A humanized IgG4 monoclonal antibody to sema4D Cancer Research. 71: 4578-4578. DOI: 10.1158/1538-7445.Am2011-4578 |
0.352 |
|
| 2011 |
Jonason AS, Fisher TL, Torno S, Bussler H, Winter LA, Kirk R, Howell A, Caplan J, Kenney P, Reilly C, Scrivens M, Huang H, Croy L, Evans EE, Paris M, ... ... Zauderer M, et al. Abstract 3667: Reduction of in vivo tumor growth and angiogenesis by a humanized IgG4 monoclonal antibody to SEMA4D Cancer Research. 71: 3667-3667. DOI: 10.1158/1538-7445.Am2011-3667 |
0.483 |
|
| 2010 |
Fisher T, Jonason A, Torno S, Bussler H, Li J, Evans EE, Watkins R, Zauderer M, Leonard JE, Smith ES. Antibody-mediated neutralization of Sema4D reduces tumor angiogenesis and growth in vivo. Journal of Clinical Oncology. 28. DOI: 10.1200/Jco.2010.28.15_Suppl.E13154 |
0.425 |
|
| 2010 |
Jonason A, Fisher T, Torno S, Bussler H, Li J, Winter L, Kirk R, Howell A, Caplan J, Kenney P, Reilly C, Scrivens M, Evans E, Paris M, Watkins R, ... Zauderer M, et al. Abstract LB-36: Antibody mediated neutralization of sema4D reduces tumor angiogenesis and growthIn Vivo. Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-36 |
0.492 |
|
| 2008 |
Bauer SM, Williams MA, Howell AP, Schwarz E, Smith ES, Zauderer M. Maximizing immune responses: the effects of covalent peptide linkage to beta-2-microglobulin. Oncology Research. 17: 205-16. PMID 18980017 DOI: 10.3727/096504008786111347 |
0.335 |
|
| 2008 |
Stirnemann K, Romero JF, Baldi L, Robert B, Cesson V, Besra GS, Zauderer M, Wurm F, Corradin G, Mach JP, Macdonald HR, Donda A. Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice. The Journal of Clinical Investigation. 118: 994-1005. PMID 18259610 DOI: 10.1172/Jci33249 |
0.479 |
|
| 2007 |
Coppage M, Belanger T, Zauderer M, Sahasrabudhe D. In vitro generation of tumor specific T cells that recognize a shared antigen of AML: molecular characterization of TCR genes. Leukemia Research. 31: 195-202. PMID 16750565 DOI: 10.1016/J.Leukres.2006.04.007 |
0.438 |
|
| 2007 |
Vermot-Desroches C, Wang W, Subiger O, Abribat T, Alberici G, Zauderer M, Ernest S. In Vitro Characterization of OP-R003-1, a New Fully Human Anti-IL6 Antibody. Blood. 110: 4522-4522. DOI: 10.1182/Blood.V110.11.4522.4522 |
0.343 |
|
| 2006 |
Evans EE, Henn AD, Jonason A, Paris MJ, Schiffhauer LM, Borrello MA, Smith ES, Sahasrabudhe DM, Zauderer M. C35 (C17orf37) is a novel tumor biomarker abundantly expressed in breast cancer. Molecular Cancer Therapeutics. 5: 2919-30. PMID 17121940 DOI: 10.1158/1535-7163.Mct-06-0389 |
0.348 |
|
| 2004 |
Smith ES, Shi S, Zauderer M. Construction of cDNA libraries in vaccinia virus. Methods in Molecular Biology (Clifton, N.J.). 269: 65-76. PMID 15114008 DOI: 10.1385/1-59259-789-0:065 |
0.556 |
|
| 2003 |
Coppage M, Belanger T, Zauderer M, Sahasrabudhe D. Generation of tumor specific T cells that recognize a shared acute myelogenous leukemia antigen Human Immunology. 64. DOI: 10.1016/J.Humimm.2003.08.129 |
0.42 |
|
| 2001 |
Choi J, Borrello MA, Smith E, Cutler CW, Sojar H, Zauderer M. Prior exposure of mice to Fusobacterium nucleatum modulates host response to Porphyromonas gingivalis. Oral Microbiology and Immunology. 16: 338-44. PMID 11737656 DOI: 10.1034/J.1399-302X.2001.160604.X |
0.316 |
|
| 2001 |
Smith ES, Mandokhot A, Evans EE, Mueller L, Borrello MA, Sahasrabudhe DM, Zauderer M. Lethality-based selection of recombinant genes in mammalian cells: application to identifying tumor antigens. Nature Medicine. 7: 967-72. PMID 11479631 DOI: 10.1038/91017 |
0.392 |
|
| 2000 |
Choi JI, Borrello MA, Smith ES, Zauderer M. Polarization of Porphyromonas gingivalis-specific helper T-cell subsets by prior immunization with Fusobacterium nucleatum. Oral Microbiology and Immunology. 15: 181-7. PMID 11154401 DOI: 10.1034/J.1399-302X.2000.150306.X |
0.366 |
|
| 2000 |
Choi J, Borrello MA, Cutler CW, Zauderer M. Prior Immunization with Fusobacterium Nucleatum Interferes with Opsonophagocytosis Function of Sera against Porphyromonas Gingivalis The Journal of the Korean Academy of Periodontology. 30: 105. DOI: 10.5051/Jkape.2000.30.1.105 |
0.322 |
|
| Show low-probability matches. |